Barcelona Progressive Supranuclear Palsy ( PSP) Registry: Clinical, Oculomotor, and Cerebrospinal Fluid Markers; from Suggestive to Definite Cases

作者：Cèlia Painous, Manel Fernández, Ana Cámara, Salut Albà-Arbalat, Marta Soto, Carla Brenlla, Esteban Muñoz, Alexandra Pérez‐Soriano, Francesc Valldeoriola, María José Martí, Eduardo Tolosa, Alícia Garrido, Almudena Sánchez‐Gómez, Laura Maragall, Anna Camós‐Carreras, Montse Tió, Nuria San Martín, M. Basora, Maríateresa Buongiorno, Maria C. Pont‐Sunyer, T. Delgado, A. Planas-Ballvé, Núria Caballol, Asunción Ávila, Dolores Vilas, Serge Jaumà, Carla Marco, Oriol de Fàbregues, Nuria Matos, Anna Mas, Natàlia Mas, Josep Maria Aragonès, Helena Bejr‐Kasem, Judith Navarro‐Otano, Elisabet Montori‐Palacín, Mircea Balasa, Jordi Sarto, Sergi Borrego‐Écija, Pedro Roldán, Andrés Perissinotti, Laura Molina‐Porcel, Ibán Aldecoa, Jessica Pérez‐Montesino, Lorena de Mena, Laura Naranjo, Raquel Ruiz‐García, Yaroslau Compta · 发表于：Movement Disorders · 年份：2025 · DOI：10.1002/mds.70086 · 被引用次数：6 · 研究领域：Parkinson's Disease Mechanisms and Treatments、Neurological disorders and treatments、Autoimmune Neurological Disorders and Treatments

BACKGROUND: Timely and accurate diagnosis of progressive supranuclear palsy (PSP) remains challenging. OBJECTIVE: To assess diagnostic certainty and progression biomarkers in the PSP spectrum from "suggestive of" (so-PSP) category as proxy of early disease, to definite (neuropathologically confirmed) cases. METHODS: Multicenter, prospective, longitudinal study of 131 participants (so-PSP, n = 23; definite, n = 5) with oculometric (n = 47) and cerebrospinal fluid (CSF) biomarkers (n = 75), compared with control (n = 18) and Parkinson's disease (PD) subjects (n = 12). RESULTS: Anti-saccade velocities were significantly reduced in so-PSP versus PD and controls. CSF α-synuclein seed amplification assay (asyn-SAA) was positive in 20% of PSP cases (vs. 100% PD and 0% controls). Longitudinally (median of 1.3 years), all probable/possible-PSP cases retained their diagnosis regardless of CSF asyn-SAA result. In so-PSP, worse saccades' variables and negative/low-fluorescence-positive asyn-SAA at baseline related to longitudinal diagnosis reinforcement. Clinical scales and neurofilament light chain (NfL) predicted shorter survival. CONCLUSIONS: Quantitative oculometry and negative/low-fluorescence-positive CSF asyn-SAA predict diagnostic validation in so-PSP. In probable/possible-PSP, positive CSF asyn-SAA may suggest copathology, although confirmation requires larger pathological studies. © 2025 International Parkinson and Movement Disorder Society.